Manufacturing problems hit Labopharm's once-daily trazodone
This article was originally published in Scrip
Executive Summary
Labopharm's once-daily formulation of the antidepressant trazodone has been hit with a complete response letter from the US FDA, which cites deficiencies of the active pharmaceutical ingredient (API) manufacturing facility.